Inarigivir (ORI-9020) ammonium is a dinucleotide antiviral drug that can significantly reduce liver HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir (ORI-9020) ammonium acts as a RIG-I (Retinoic acid-inducible gene-I) agonist to activate cellular innate immune responses In Vitro Inarigivir (SB 9200) is active against HBV variants carrying resistance markers against all the nucleos(t)ide analogues approved for treating chronic hepatitis B. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Inarigivir (100 mg/kg/day, ip) significantly reduces viral DNA in the liver and shows anti-HBV activity. Serum HBV DNA is not reduced in response to treatment. Inarigivir does not affect levels of HBV RNA in liver, levels of HBeAg in serum, or mean titers of HBsAg. The minimal effective dose is identified to be between 1.6 and 0.5 mg/kg/day using liver HBV DNA values . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mice Dosage: 100 mg/kg. Administration: IP, daily. Result: Significantly reduced viral DNA in the liver and shows anti-HBV activity similar ADV positive control. Form:Solid IC50& Target:Target: HBV